Chart: "The Pink Sheet" Index Of NYSE Pharmaceutical Stocks: 2004
You may also be interested in...
After reaching several corporate milestones in 2004, Amgen enters the New Year with two goals: preserving its entrepreneurial image as it joins the top tier of the pharma industry and putting the finishing touches on a growth plan that could reinvent the very model of big pharma
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials